- Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Coronary Artery Disease
Interventions: Device: PROMUS Element Plus Coronary Stent System; Drug: Aspirin; Drug: P2Y12 antagonist
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Not yet recruiting - verified May 2012 - Condition: Impaired Glucose Tolerance
Interventions: Dietary Supplement: Resveratrol; Dietary Supplement: resveratrol /HMB; Other: Placebo treatment
Sponsors: Vanderbilt University; Vanderbilt University; Nutraceutical Discoveries, Inc.
Recruiting - verified May 2012 - Conditions: Tendinosis; Tendinitis
Interventions: Procedure: Tenotomy; Drug: Ultrasound guided percutaneous platelet rich plasma injection
Sponsors: University of Michigan; University of Michigan
Recruiting - verified May 2012 - Conditions: Asthma, Aspirin-Induced; Aspirin Exacerbated Asthma
Intervention: Drug: Prasugrel
Sponsors: Brigham and Women's Hospital; Elliot Israel, MD; Brigham and Women's Hospital
Not yet recruiting - verified May 2012 - Condition: Bioequivalence
Interventions: Drug: Flector patch; Device: Microdialysis probe
Sponsors: University of Florida; University of Florida; Food and Drug Administration (FDA)
Recruiting - verified May 2012 - Condition: Acute Low Back Pain
Interventions: Drug: Naproxen; Drug: Cyclobenzaprine; Drug: Oxycodone/ acetaminophen
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Not yet recruiting - verified April 2012 - Condition: Brain Tumor
Intervention: Drug: Sulfasalazine
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012 - Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: salsalate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Ischemic Stroke; Transient Ischemic Attack (TIA)
Intervention: Other: Vitamin E tocotrienol (TCT) pills ; Low dose Aspirin
Sponsors: Ohio State University; Chandan K Sen; Government of Malaysia
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: Standard dose BG00012; Drug: Aspirin placebo; Drug: Aspirin; Drug: Escalating doses of BG00012; Drug: BG00012 placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Pain
Interventions: Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen; Drug: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Headache
Interventions: Drug: BAY1019036; Drug: Acetaminophen; Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy; Drug: TNF inhibitors
Sponsors: Columbia University; Columbia University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2012 - Condition: Preeclampsia
Interventions: Drug: Aspirin; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified March 2012 - Condition: Other Acute Postoperative Pain
Interventions: Drug: Indomethacin; Drug: Indomethacin; Drug: Indomethacin; Drug: Celecoxib; Drug: Placebo
Sponsors: Iroko Pharmaceuticals, LLC; Iroko Pharmaceuticals, LLC
Recruiting - verified February 2012 - Condition: Healthy Controls
Interventions: Radiation: Integrated MR-PET scan; Drug: Ketorolac; Drug: Morphine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: Osteoarthritis, Knee
Interventions: Drug: Naproxen; Drug: Placebo
Sponsors: Analgesic Solutions; Analgesic Solutions
Recruiting - verified February 2012 - Condition: Cardiovascular Disease
Interventions: Dietary Supplement: ResA; Dietary Supplement: Resveratrol; Dietary Supplement: Placebo
Sponsors: University of California, Davis; University of California, Davis; Gateway Health Alliance
Not yet recruiting - verified March 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine; Drug: Prednisone; Drug: Corticosteroids followed by mesalamine (Pentasa)
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified April 2012 - Condition: Fever
Interventions: Drug: Intravenous Ibuprofen; Drug: Acetaminophen (Standard of Care)
Sponsors: Columbia University; Columbia University; Cumberland Pharmaceuticals
Recruiting - verified February 2012 - Condition: Epicondylitis of the Elbow
Interventions: Drug: Naproxen; Drug: Synera patch twice daily; Drug: Synera patch for 12hrs/day; Drug: Naproxen; Drug: Synera; Drug: Synera
Sponsors: International Clinical Research Institute; International Clinical Research Institute
Not yet recruiting - verified January 2012 - Condition: Acne Vulgaris
Interventions: Drug: Epiduo Gel; Drug: Retin-A Micro Microsphere 0.1%
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: Anti-inflammatory Combination Therapy; Drug: Placebo
Sponsors: University of Maryland; University of Maryland
Not yet recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Osteoarthritis of the Knee; Coagulopathy
Intervention: Drug: PENNSAID (diclofenac sodium solution topical)
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; Covidien; Arthritis Treatment Center, Maryland
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PL2200 Aspirin Capsules; Drug: Immediate-Release Aspirin Tablets; Drug: Enteric-coated aspirin caplets
Sponsors: PLx Pharma; PLx Pharma
Recruiting - verified January 2012 - Conditions: Neuralgia; Postherpetic Neuralgia; Reflex Sympathetic Dystrophy
Interventions: Drug: Pennsaid topical 1.5% diclofenac; Drug: Placebo (2.3% DMSO solution)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified March 2012 - Conditions: Anemia; Unexplained Anemia
Interventions: Drug: Salsalate; Drug: Salsalate placebo
Sponsors: Duke University; Duke University; National Institute on Aging (NIA)
Not yet recruiting - verified January 2012 - Condition: Acute Respiratory Distress Syndrome
Interventions: Drug: Aspirin; Drug: Lactose powder
Sponsors: Mayo Clinic; Ognjen Gajic; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Vanderbilt University
Not yet recruiting - verified January 2012 - Condition: Acne Vulgaris
Interventions: Drug: Adapalene + benzoyl peroxide samples; Drug: Adapalene + benzoyl peroxide from standard tube
Sponsors: Wake Forest University; Wake Forest University; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Immunex Corporation
Recruiting - verified February 2012 - Condition: Alzheimer's Disease
Interventions: Drug: Resveratrol; Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012 - Condition: Postoperative Dental Pain
Interventions: Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Postsurgical Dental Implant Surgery Pain
Intervention: Drug: Ketorolac Tromethamine Nasal Spray
Sponsors: Hersh, Elliot V., DMD, MS, PhD; Hersh, Elliot V., DMD, MS, PhD
Recruiting - verified December 2011 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Salsalate; Drug: Salsalate
Sponsors: Indiana University; Indiana University
Recruiting - verified February 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012 - Conditions: Peripheral Neuropathy; Type 1 Diabetes
Intervention: Drug: Salsalate
Sponsors: University of Michigan; University of Michigan
Recruiting - verified December 2011 - Condition: Allergic Conjunctivitis
Interventions: Drug: AL-4943A Ophthalmic Solution; Drug: AL-4943A Ophthalmic Solution Vehicle; Drug: Pataday
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: Senile Purpura
Intervention: Drug: adapalene gel 0.3%
Sponsors: Multispecialty Aesthetic Clinical Research Organization; Multispecialty Aesthetic Clinical Research Organization; Galderma Laboratories, L.P.
Recruiting - verified April 2012 - Condition: Migraine
Interventions: Drug: Ketorolac; Drug: Placebo
Sponsors: Akron Children's Hospital; Akron Children's Hospital
Recruiting - verified February 2012 - Condition: Neuroendocrine Tumor
Intervention: Dietary Supplement: Resveratrol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Myopia
Intervention: Drug: Bromfenac
Sponsors: Virdi Eye Clinic; Virdi Eye Clinic
Recruiting - verified November 2011 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Intervention: Behavioral: painACTION: Arthritis
Sponsors: Inflexxion, Inc.; Inflexxion, Inc.
Recruiting - verified October 2011 - Condition: Retraction of Colostomy
Interventions: Drug: Morphine Sulfate; Drug: bupivacaine liposome extended-release injectable suspension
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Retraction of Colostomy
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV Morphine Sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified April 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: EXPAREL (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome extended-release injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV Morphine Sulfate; Drug: SKY0402 (bupivacaine liposome extended-release injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: morphine sulfate; Drug: bupivacaine liposome extended-release injectable suspension
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Conditions: Uterine Fibroids; Uterine Artery Embolization
Interventions: Drug: pregabalin/celecoxib; Drug: pregabalin/placebo; Drug: celecoxib/placebo; Drug: Placebo group
Sponsors: Northwestern University; Northwestern University
Recruiting - verified March 2012 - Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified April 2012 - Conditions: Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy
Interventions: Drug: SPI-1005 Low Dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High Dose; Drug: Placebo
Sponsors: Sound Pharmaceuticals, Incorporated; Sound Pharmaceuticals, Incorporated; VA Puget Sound Health Care System
Not yet recruiting - verified October 2011 - Condition: Eye Allergies
Interventions: Drug: Olopatadine hydrochloride 0.2%; Drug: Bepotastine besilate ophthalmic solution 1.5%
Sponsors: McCabe Vision Center; McCabe Vision Center
Recruiting - verified October 2011 - Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011 - Condition: Temporary Auditory Threshold Shift
Interventions: Drug: SPI-1005 Low dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High dose; Drug: Placebo
Sponsors: Sound Pharmaceuticals, Incorporated; Sound Pharmaceuticals, Incorporated; University of Florida
Recruiting - verified October 2011 - Condition: Bipolar Depression
Interventions: Drug: ESC + CBX; Drug: ESC + PBO.; Drug: ESC+CBX
Sponsors: Loyola University; Loyola University; Stanley Medical Research Institute
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Bipolar Disorder Depression
Interventions: Drug: Minocycline; Drug: Aspirin; Drug: placebo
Sponsors: Laureate Institute for Brain Research, Inc.; Laureate Institute for Brain Research, Inc.; Stanley Medical Research Institute; University of Oklahoma
Recruiting - verified March 2012 - Condition: Post-surgical Dental Pain
Interventions: Drug: PF-04531083; Other: Placebo; Drug: PF-04531083; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Interventions: Drug: diclofenac sodium topical gel; Other: Placebo
Sponsors: Brown, Theodore R., M.D., MPH; Brown, Theodore R., M.D., MPH; Teva Neuroscience, Inc.
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tetrahydrobiopterin (BH4); Drug: non-acetylated salicylate; Dietary Supplement: High Fat Meal; Drug: L-NMMA; Dietary Supplement: Antioxidant Cocktail
Sponsors: Georgia Health Sciences University; Georgia Health Sciences University; American Heart Association
Recruiting - verified July 2011 - Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: CAD
Intervention:
Sponsors: Creighton University; Creighton University
Recruiting - verified January 2012 - Condition: Inflammatory Response
Interventions: Drug: Ibuprofen; Drug: Placebo/Saline solution
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified June 2011 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Conditions: Post Infective IBS-D; Irritable Bowel Syndrome With Diarrhea
Intervention: Drug: Mesalamine
Sponsors: University of Utah; University of Utah; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Other: Diclofenac epolamine patch
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Condition: Knee Osteoarthritis
Intervention: Drug: Voltaren
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Endo Pharmaceuticals
Recruiting - verified June 2011 - Conditions: Age-associated Cognitive Impairment; Mild Cognitive Impairment (MCI)
Interventions: Dietary Supplement: Curcumin; Dietary Supplement: Sugar pill
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2012 - Conditions: Osteoarthritis; Chronic Pain
Intervention: Drug: duloxetine, diclofenac
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Research Resources (NCRR); Merck; Nuvo Research Inc.
Recruiting - verified March 2012 - Condition: Pain, Postoperative
Intervention: Drug: Ketolorac
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Not yet recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Pirfenidone; Drug: Placebo
Sponsors: InterMune; InterMune
Recruiting - verified June 2011 - Condition: Chronic Kidney Disease
Intervention:
Sponsors: North Shore Long Island Jewish Health System; Staten Island University Hospital
Recruiting - verified April 2011 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Pain
Interventions: Drug: Ketorolac; Drug: Ibuprofen
Sponsors: Planned Parenthood League of Massachusetts; Planned Parenthood League of Massachusetts; Society of Family Planning
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011 - Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: naproxen; Drug: esomeprazole
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2011 - Condition: Impaired Glucose Tolerance
Interventions: Dietary Supplement: resveratrol; Drug: Placebo
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; American Diabetes Association
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol
Sponsors: University of North Dakota; University of North Dakota; Department of Defense
Recruiting - verified August 2011 - Conditions: Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor; Drug: Cyclophosphamide; Drug: Celecoxib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Diabetic Macular Edema
Interventions: Drug: nepafenac 0.1% drops; Other: Nepafenac Vehicle
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified November 2011 - Conditions: Pain; Fever
Intervention: Drug: Intravenous ibuprofen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pain
Intervention: Drug: Intravenous ibuprofen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Tonsillectomy
Interventions: Drug: Intravenous ibuprofen; Other: Normal Saline
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified January 2012 - Condition: Menstrual Migraine
Interventions: Drug: sumatriptan/naproxen sodium; Drug: placebo
Sponsors: Cady, Roger, M.D.; Cady, Roger, M.D.; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Acute Sore Throat
Intervention: Device: Ear Acupuncture
Sponsors: Mike O'Callaghan Federal Hospital; Mike O'Callaghan Federal Hospital
Recruiting - verified April 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib; Drug: Vorinostat; Drug: Dexamethasone; Drug: Methotrexate; Drug: Imatinib mesylate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Colon Cancer
Interventions: Dietary Supplement: curcumin; Dietary Supplement: Curcumin conjugated with plant exosomes; Other: No intervention
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Postmenopausal Osteoporosis; Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified November 2011 - Condition: Pain
Interventions: Drug: Fentanyl; Drug: Fentanyl; Drug: Oxycodone/acetaminophen; Drug: oxycodone/acetaminophen
Sponsors: University of Oklahoma; Stephen Thomas; University of Oklahoma
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Curcumin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Conditions: Laceration; Pain
Interventions: Drug: Ibuprofen; Drug: Oxycodone; Other: Placebo
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's Hospitals and Clinics of Minnesota
Not yet recruiting - verified November 2011 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: VT-122 (propranolol plus etodolac); Drug: Placebo
Sponsors: Vicus Therapeutics; Vicus Therapeutics
Recruiting - verified May 2012 - Condition: Acute Migraine
Interventions: Drug: Metoclorpamide; Drug: Ketorolac; Drug: Valproate
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Conditions: Mesolthelioma; Esophageal Cancer; Lung Cancer
Interventions: Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Episodic Migraine; Chronic Migraine
Interventions: Drug: Aspirin (acetylsalicylic acid); Drug: Placebo
Sponsors: Swedish Medical Center; Swedish Medical Center; University of Washington; National Headache Foundation; Wadsworth Foundation; Accumetrics, Inc.
Recruiting - verified July 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Hydroxyurea; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified December 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Radiation-induced Dermatitis
Intervention: Drug: Curcumin
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Cancer Patients Who Are Undergoing Chemotherapy Treatments and Are Experiencing Cognitive Difficulties.
Interventions: Drug: Ibuprofen; Behavioral: Home-Based Exercise (EXCAP); Drug: Placebo (sugar pill)
Sponsors: University of Rochester; University of Rochester; National Institutes of Health (NIH)
Recruiting - verified August 2011 - Condition: Episodic Migraine
Interventions: Other: saline placebo; Drug: Ibuprofen
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified June 2011 - Conditions: Migraine Disorders; Migraine Headache; Migraine; Acute Migraine
Interventions: Drug: Topical, intra-oral ketoprofen gel; Other: Placebo gel
Sponsors: Behar, Caren, M.D.; Behar, Caren, M.D.
Not yet recruiting - verified October 2010 - Condition: Head And Neck Cancer
Interventions: Other: Placebo; Drug: Curcumin; Drug: Armodafinil; Drug: Minocycline; Drug: Bupropion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Part I - etoricoxib 60 mg; Drug: Part I - etoricoxib 90 mg; Drug: Part I- naproxen 1000 mg; Drug: Part I - Placebo to etoricoxib 60 mg; Drug: Part I - Placebo to etoricoxib 90 mg; Drug: Part I - Placebo to naproxen 500 mg; Drug: Part II- etoricoxib 60 mg; Drug: Part II- etoricoxib 90 mg; Drug: Part II- naproxen 1000 mg; Drug: Part II - Placebo to etoricoxib 60 mg; Drug: Part II - Placebo to etoricoxib 90 mg; Drug: Part II - Placebo to naproxen 500 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Spinal Cord Injury
Intervention: Drug: Salsalate
Sponsors: University of Miami; University of Miami
Recruiting - verified November 2011 - Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified October 2011 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Placebo infusion; Drug: ibuprofen intravenous
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey
Recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Interventions: Biological: Humira (adalimumab); Drug: Methotrexate (MTX)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Erlotinib; Drug: Sulindac; Drug: Placebo A; Drug: Placebo B
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Lung Inflammation
Interventions: Drug: Rosiglitazone; Drug: Zileuton; Drug: Rosiglitazone placebo; Drug: Zileuton placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Doris Duke Charitable Foundation
Recruiting - verified July 2011 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified April 2012 - Condition: Menorrhagia
Interventions: Drug: Estradiol 30 mcg / Levonorgestrel 150 mcg monophasic oral contraceptive pills; Drug: Naproxen sodium pills; Device: Nova Sure Radiofrequency Endometrial Ablation
Sponsors: Mayo Clinic; Mayo Clinic; Hologic, Inc.
Recruiting - verified January 2012 - Condition: Coronary Graft Patency
Interventions: Drug: clopidogrel; Drug: sugar pill
Sponsors: Brooke Army Medical Center; Ahmad Slim; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Intervention: Dietary Supplement: Microgranular Curcumin C3 Complex®
Sponsors: Louisiana State University Health Sciences Center Shreveport; Louisiana State University Health Sciences Center Shreveport; Feist-Weiller Cancer Center at Louisiana State University Health Sciences; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Lung Cancer; Esophageal Cancer; Malignant Pleural Mesothelioma; Thymoma; Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; Drug: cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Migraine
Interventions: Drug: sumatriptan/naproxen sodium; Drug: Placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; University of Michigan; University of Toledo Health Science Campus; Dartmouth-Hitchcock Medical Center
Recruiting - verified August 2011 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Zileuton
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012 - Condition: Ulcerative Colitis
Interventions: Drug: MMX Mesalamine; Drug: MMX Mesalamine; Drug: MMX Mesalamine
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Condition: Sickle Cell Disease
Intervention: Drug: Zileuton
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit; Drug: Etoposide; Drug: Intrathecal Methotrexate; Drug: hydrocortisone
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Condition: Chronic Beryllium Disease
Interventions: Drug: Mesalamine; Drug: Placebo
Sponsors: National Jewish Health; National Jewish Health
Recruiting - verified December 2011 - Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Recruiting - verified December 2011 - Condition: Migraine Disorders
Interventions: Drug: Sumatriptan; Drug: Naratriptan; Drug: Sumatriptan-naproxen combination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Post-Traumatic Headache
Interventions: Drug: sumatriptan/naproxen sodium; Drug: Placebo
Sponsors: Cady, Roger, M.D.; Cady, Roger, M.D.; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Procedure: Aspirin ingestion followed by doing a Bleeding Volume Test; Procedure: Gatorade Placebo followed by Bleeding Volume Test.
Sponsors: Klein, Jeffrey A., M.D.; Klein, Jeffrey A., M.D.
Recruiting - verified June 2011 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Diverticulitis
Interventions: Drug: Mesalazine; Drug: Mesalazine; Drug: Placebo
Sponsors: Dr. Falk Pharma GmbH; Dr. Falk Pharma GmbH
Recruiting - verified January 2012 - Conditions: Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding
Interventions: Drug: 100 mg enteric-coated aspirin; Drug: Placebo
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation; National Health and Medical Research Council, Australia; Bayer; Monash University; Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011 - Conditions: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week); Drug: Chloroquine Low Dose (250mg/week); Procedure: Breast Biopsy
Sponsors: Inova Health Care Services; Inova Health Care Services; George Mason University; Department of Defense; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012 - Condition: Headache
Interventions: Drug: Metoclopramide; Drug: Ketorolac
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified February 2012 - Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide; Drug: Placebo; Behavioral: Formal weight loss counselling program
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; National Eye Institute (NEI); University of Rochester; University of Iowa; University of California, Davis
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011 - Condition: Fever
Interventions: Drug: ibuprofen; Drug: acetaminophen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified March 2012 - Condition: Glaucoma
Interventions: Drug: Prednisolone 1%; Drug: Diclofenac 0.1%; Drug: Artificial Tears
Sponsors: University of Miami; University of Miami; Bascom Palmer Eye Institute; University of Pittsburgh
Recruiting - verified August 2011 - Condition: Familial Adenomatous Polyposis
Interventions: Drug: eflornithine (DFMO); Drug: acetylsalicylic acid (aspirin); Other: placebo; Other: laboratory biomarker analysis; Other: gene expression analysis; Other: telephone-based intervention; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: protein expression analysis
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: PEG-asparaginase; Drug: Cytarabine; Drug: Methotrexate; Drug: Imatinib; Drug: Clofarabine; Drug: 6 Mercaptopurine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Enzon Pharmaceuticals, Inc.; Genzyme
Recruiting - verified April 2012 - Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Curcumin (Turmeric); Behavioral: Questionnaires; Other: Photos
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011 - Condition: Mouth Neoplasms
Interventions: Drug: 1,25-dihydroxyvitamin D3; Drug: celecoxib; Drug: 1,25-dihydroxyvitamin D3 + celecoxib
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Dasatinib, Mitoxantrone, Cytarabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Psoriasis
Interventions: Drug: Methotrexate; Drug: Adalimumab (Humira)
Sponsors: Tufts Medical Center; Tufts Medical Center; Abbott
Recruiting - verified July 2011 - Condition: Leukemia, Lymphocytic, Acute
Interventions: Drug: Methotrexate; Drug: Vincristine; Drug: PEG-l-asparaginase; Drug: Dexamethasone; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Migraine With Aura
Interventions: Drug: sumatriptan with naprosyn; Drug: placebo
Sponsors: Dent Neurologic Institute; Dent Neurologic Institute
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type I
Interventions: Biological: Purified Pancreatic Islets; Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cytarabine; Drug: decitabine; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Condition: Migraine Headache
Interventions: Drug: Treximet (Imitrex + naproxen sodium); Other: Inert Placebo
Sponsors: University of Toledo Health Science Campus; University of Toledo Health Science Campus; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Leprosy
Intervention: Drug: clofazamine
Sponsors: Kaiser Permanente; Kaiser Permanente; National Hansen's Disease Program
Available - verified April 2012 - Conditions: Mucocutaneous Lymph Node Syndrome; Kawasaki Disease
Interventions: Drug: Etanercept; Drug: Placebo
Sponsors: Seattle Children's Hospital; Michael Portman; FDA Office of Orphan Products Development; Amgen
Recruiting - verified April 2012 - Conditions: Psoriasis; Melanoma; Non-melanoma Skin Cancer
Intervention: Drug: etanercept
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Amgen
Recruiting - verified August 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Adalimumab
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Bronchitis
Intervention: Drug: Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Sponsors: National Institute of Environmental Health Sciences (NIEHS); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified August 2009 - Condition: Patent Ductus Arteriosus
Interventions: Other: feeding; Other: fasting
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Acute Graft Versus Host Disease
Intervention: Drug: Etanercept (Enbrel)
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified September 2011 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Islets of Langerhans transplantation
Sponsors: University of Illinois; University of Illinois
Recruiting - verified August 2011 - Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy; Drug: etanercept
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Ulcerative Colitis
Intervention: Drug: mesalamine
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Shire Development LLC
Recruiting - verified December 2011 - Condition: Familial Adenomatous Polyposis
Interventions: Dietary Supplement: curcumin; Drug: placebo
Sponsors: Johns Hopkins University; Johns Hopkins University
Recruiting - verified March 2012 - Condition: Graft Versus Host Disease
Interventions: Procedure: stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: etanercept; Drug: methoxsalen
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Therakos; Amgen
Recruiting - verified November 2011 - Conditions: Coronary Artery Disease; Overweight
Interventions: Drug: Salsalate; Drug: Placebo
Sponsors: Joslin Diabetes Center; Allison Goldfine; Beth Israel Deaconess Medical Center; Tufts Medical Center
Recruiting - verified March 2012 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Drug: Aspirin
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified March 2012 - Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: celebrex (celecoxib); Drug: placebo capsules
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Intervention: Drug: Pimecrolimus
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.; Clinical Research Computing Unit (University of Pennsylvania)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Drug: celecoxib; Drug: Docetaxel; Drug: pemetrexed disodium; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Obstetric Labor, Premature
Intervention: Drug: Indomethacin and Nifedipine
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Conditions: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension
Intervention: Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Amgen
Recruiting - verified February 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011 - Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010 - Condition: Multiple Sclerosis
Intervention: Drug: Aspirin
Sponsors: Mayo Clinic; Mayo Clinic; National Multiple Sclerosis Society
Recruiting - verified November 2011 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Condition: Precancerous Conditions
Intervention: Drug: Erlotinib & Celecoxib
Sponsors: Emory University; Emory University; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Conditions: Leukoplakia, Oral; Benign Neoplasms
Interventions: Drug: sulindac; Drug: Placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amrita Institute of Sciences, AIMS, Cochin, India; Weill Medical College of Cornell University; Regional Cancer Center(RCC), Trivandrum, India; Narayana Hrudayalaya Hospitals
Recruiting - verified January 2012 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Conditions: Tachycardia; Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide; Drug: Atomoxetine; Other: Baseline (No Drug); Drug: Clonidine; Drug: Entacapone; Drug: Entacapone & Propranolol; Drug: Atomoxetine & Propranolol; Drug: Indomethacin; Drug: Mecamylamine; Drug: Isosorbide Dinitrate; Dietary Supplement: Melatonin; Drug: Midodrine; Drug: Modafinil; Drug: Octreotide; Radiation: Placebo; Drug: Propranolol; Drug: Modafinil & Propranolol; Drug: Sertraline; Procedure: IV Saline; Other: Drinking Water; Device: Breathing Device; Drug: memantine; Device: Abdominal binder
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention: Drug: Oxaliplatin, Capecitabine, Celecoxib with Radiation
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Coronary Arteriosclerosis
Interventions: Drug: HOE 140; Drug: Aminocaproic Acid; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified July 2011 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Pancreas Neoplasms
Intervention: Drug: celecoxib
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012 - Condition: Lung Cancer
Intervention: Drug: celecoxib
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
 |
Anti Inflammatory Agents Non Steroidal Clinical Trials |
